135 related articles for article (PubMed ID: 37012339)
41. CRISPRs and epigenome editing.
Rusk N
Nat Methods; 2014 Jan; 11(1):28. PubMed ID: 24524135
[No Abstract] [Full Text] [Related]
42. [An history of the CRISPR-Cas systems discovery].
Pourcel C
Biol Aujourdhui; 2017; 211(4):247-254. PubMed ID: 29956651
[TBL] [Abstract][Full Text] [Related]
43. Nuclease-Deficient Clustered Regularly Interspaced Short Palindromic Repeat-Based Approaches for
Lek A; Ma K; Woodman KG; Lek M
Hum Gene Ther; 2021 Mar; 32(5-6):260-274. PubMed ID: 33446040
[TBL] [Abstract][Full Text] [Related]
44. New Insights into CRISPR Arrays.
Pourcel C
CRISPR J; 2020 Dec; 3(6):422-424. PubMed ID: 33346709
[No Abstract] [Full Text] [Related]
45. Targeted mutagenesis in Zea mays using TALENs and the CRISPR/Cas system.
Liang Z; Zhang K; Chen K; Gao C
J Genet Genomics; 2014 Feb; 41(2):63-8. PubMed ID: 24576457
[TBL] [Abstract][Full Text] [Related]
46. CRISPR-Cas9 can cause chromothripsis.
Urnov FD
Nat Genet; 2021 Jun; 53(6):768-769. PubMed ID: 34103715
[No Abstract] [Full Text] [Related]
47. CRISPR
Barrangou R
CRISPR J; 2022 Apr; 5(2):170. PubMed ID: 35438513
[No Abstract] [Full Text] [Related]
48. Refining CRISPR-based genome and epigenome editing off-targets.
Luo Y
Cell Biol Toxicol; 2019 Aug; 35(4):281-283. PubMed ID: 31227932
[No Abstract] [Full Text] [Related]
49. CRISPR gets the glory in landmark approval, but haemoglobin research made it possible.
Mullard A
Nat Rev Drug Discov; 2024 Jan; 23(1):14-15. PubMed ID: 38012387
[No Abstract] [Full Text] [Related]
50. Better Guidance for CRISPR.
Barrangou R
CRISPR J; 2022 Dec; 5(6):741. PubMed ID: 36512349
[No Abstract] [Full Text] [Related]
51. The future of CRISPR technologies in agriculture.
Gao C
Nat Rev Mol Cell Biol; 2018 May; 19(5):275-276. PubMed ID: 29382940
[No Abstract] [Full Text] [Related]
52. CRISPR technology.
Nat Biotechnol; 2022 Jun; 40(6):832. PubMed ID: 35705705
[No Abstract] [Full Text] [Related]
53. Detection of CRISPR adaptation.
Shiriaeva A; Fedorov I; Vyhovskyi D; Severinov K
Biochem Soc Trans; 2020 Feb; 48(1):257-269. PubMed ID: 32010936
[TBL] [Abstract][Full Text] [Related]
54. Proof-of-principle Intellia trial shows in vivo CRISPR activity.
Mullard A
Nat Rev Drug Discov; 2022 Apr; 21(4):249. PubMed ID: 35277676
[No Abstract] [Full Text] [Related]
55. Whole-body CRISPR editing.
Perdigoto CN
Nat Struct Mol Biol; 2022 Aug; 29(8):729. PubMed ID: 35948771
[No Abstract] [Full Text] [Related]
56. Editorial: CRISPR and alternative approaches.
Kapusi E; Cong L; Stoger E
Biotechnol J; 2022 Jul; 17(7):e2200290. PubMed ID: 35726663
[No Abstract] [Full Text] [Related]
57. CRISPR Rewrites the Future of Medicine.
Barrangou R
CRISPR J; 2022 Feb; 5(1):1. PubMed ID: 35191754
[No Abstract] [Full Text] [Related]
58. Cardiac defect corrected in vivo with CRISPR.
Fudge JB
Nat Biotechnol; 2023 Mar; 41(3):323. PubMed ID: 36922689
[No Abstract] [Full Text] [Related]
59. Assessing Off-Target Editing of CRISPR-Cas9 Systems.
Pruett-Miller SM
CRISPR J; 2020 Dec; 3(6):430-432. PubMed ID: 33346715
[No Abstract] [Full Text] [Related]
60. Combination therapy for HCC: from CRISPR screening to the design of clinical therapies.
Wang Y; Kui L; Wang G
Signal Transduct Target Ther; 2021 Oct; 6(1):359. PubMed ID: 34608130
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
